Literature DB >> 19624570

B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans.

F Porcheray1, W Wong, S L Saidman, J De Vito, T C Girouard, M Chittenden, J Shaffer, N Tolkoff-Rubin, B R Dey, T R Spitzer, R B Colvin, A B Cosimi, T Kawai, D H Sachs, M Sykes, E Zorn.   

Abstract

Five patients with end-stage kidney disease received combined kidney and bone marrow transplants from HLA haploidentical donors following nonmyeloablative conditioning to induce renal allograft tolerance. Immunosuppressive therapy was successfully discontinued in four patients with subsequent follow-up of 3 to more than 6 years. This allograft acceptance was accompanied by specific T-cell unresponsiveness to donor antigens. However, two of these four patients showed evidence of de novo antibodies reactive to donor antigens between 1 and 2 years posttransplant. These humoral responses were characterized by the presence of donor HLA-specific antibodies in the serum with or without the deposition of the complement molecule C4d in the graft. Immunofluorescence staining, ELISA assays and antibody profiling using protein microarrays demonstrated the co-development of auto- and alloantibodies in these two patients. These responses were preceded by elevated serum BAFF levels and coincided with B-cell reconstitution as revealed by a high frequency of transitional B cells in the periphery. To date, these B cell responses have not been associated with evidence of humoral rejection and their clinical significance is still unclear. Overall, our findings showed the development of B-cell allo- and autoimmunity in patients with T-cell tolerance to the donor graft.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19624570      PMCID: PMC2837587          DOI: 10.1111/j.1600-6143.2009.02738.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  22 in total

1.  Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages.

Authors:  P C Grimm; R McKenna; P Nickerson; M E Russell; J Gough; E Gospodarek; B Liu; J Jeffery; D N Rush
Journal:  J Am Soc Nephrol       Date:  1999-07       Impact factor: 10.121

2.  Maintenance of serological memory by polyclonal activation of human memory B cells.

Authors:  Nadia L Bernasconi; Elisabetta Traggiai; Antonio Lanzavecchia
Journal:  Science       Date:  2002-12-13       Impact factor: 47.728

3.  Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation.

Authors:  James C Fang; Scott Kinlay; Dominik Behrendt; Hiroyuki Hikita; Joseph L Witztum; Andrew P Selwyn; Peter Ganz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

4.  Predominant autoantibody production by early human B cell precursors.

Authors:  Hedda Wardemann; Sergey Yurasov; Anne Schaefer; James W Young; Eric Meffre; Michel C Nussenzweig
Journal:  Science       Date:  2003-08-14       Impact factor: 47.728

5.  All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies.

Authors:  Po-Chang Lee; Paul I Terasaki; Steven K Takemoto; Po-Huang Lee; Chung-Jye Hung; Yi-Lin Chen; Alen Tsai; Huan-Yao Lei
Journal:  Transplantation       Date:  2002-10-27       Impact factor: 4.939

6.  The proteasome is a major autoantigen in multiple sclerosis.

Authors:  Isabel Mayo; Joaquín Arribas; Pablo Villoslada; Rita Alvarez DoForno; Susana Rodríguez-Vilariño; Xavier Montalban; María Rosa De Sagarra; José G Castaño
Journal:  Brain       Date:  2002-12       Impact factor: 13.501

7.  Antiphospholipid antibodies as a risk factor for atherosclerotic events in renal transplant recipients.

Authors:  Didier Ducloux; Emmanuelle Bourrinet; Gérard Motte; Jean-Marc Chalopin
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

Review 8.  Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies.

Authors:  Laura M Stinton; Theophany Eystathioy; Sanja Selak; Edward K L Chan; Marvin J Fritzler
Journal:  Clin Immunol       Date:  2004-01       Impact factor: 3.969

9.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Corey S Cutler; Nazmim S Bhuiya; Michael Schowalter; Vincent T Ho; Edwin P Alyea; John Koreth; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

10.  Clinical significance of anti-endothelial cell antibody in renal transplant recipients.

Authors:  Y S Shin; C W Yang; H J Ahn; C W Park; D C Jin; Y S Kim; Y S Chang; B K Bang
Journal:  Korean J Intern Med       Date:  2001-03       Impact factor: 2.884

View more
  28 in total

Review 1.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

Review 2.  B cells and transplantation tolerance.

Authors:  Allan D Kirk; Nicole A Turgeon; Neal N Iwakoshi
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

Review 3.  Molecular diagnostics in transplantation.

Authors:  Maarten Naesens; Minnie M Sarwal
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

Review 4.  The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Authors:  Jeffrey A Bluestone; Hugh Auchincloss; Gerald T Nepom; Daniel Rotrosen; E William St Clair; Laurence A Turka
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

5.  Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.

Authors:  Pervinder Sagoo; Esperanza Perucha; Birgit Sawitzki; Stefan Tomiuk; David A Stephens; Patrick Miqueu; Stephanie Chapman; Ligia Craciun; Ruhena Sergeant; Sophie Brouard; Flavia Rovis; Elvira Jimenez; Amany Ballow; Magali Giral; Irene Rebollo-Mesa; Alain Le Moine; Cecile Braudeau; Rachel Hilton; Bernhard Gerstmayer; Katarzyna Bourcier; Adnan Sharif; Magdalena Krajewska; Graham M Lord; Ian Roberts; Michel Goldman; Kathryn J Wood; Kenneth Newell; Vicki Seyfert-Margolis; Anthony N Warrens; Uwe Janssen; Hans-Dieter Volk; Jean-Paul Soulillou; Maria P Hernandez-Fuentes; Robert I Lechler
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

Review 6.  Induction of tolerance through mixed chimerism.

Authors:  David H Sachs; Tatsuo Kawai; Megan Sykes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 7.  Biologic agents in islet transplantation.

Authors:  Boris Gala-Lopez; Andrew R Pepper; A M James Shapiro
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

8.  Transplantation: Autoantibodies-epiphenomena or biological clues.

Authors:  Philip F Halloran
Journal:  Nat Rev Nephrol       Date:  2013-10-22       Impact factor: 28.314

9.  Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes.

Authors:  Maarten Naesens; Purvesh Khatri; Li Li; Tara K Sigdel; Matthew J Vitalone; Rong Chen; Atul J Butte; Oscar Salvatierra; Minnie M Sarwal
Journal:  Kidney Int       Date:  2011-08-31       Impact factor: 10.612

10.  Combining Treg therapy with mixed chimerism: Getting the best of both worlds.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Chimerism       Date:  2010 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.